SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Twilio, Inc. engages in the development of communications software, cloud-based platforms, and services. It operates through Twilio Communications and Twilio Segments. The Twilio Communications segment includes the platforms Messaging and Voice. The Twilio Segment involves Segment, Engage, Flex, Email, and others. The company was founded by John Wolthuis, Jeffery G. Lawson, and Evan Cooke in March 2008 and is headquartered in San Francisco, CA.

Twilio Inc - Ordinary Shares Class A

Twilio Inc

Twilios latest earnings beat and raised full-year outlook were overshadowed by softer fourth-quarter organic-growth guidance, signaling a slowdown from the prior quarter. Traders are debating whether the selloff is an overreaction to the outlook or a justified repricing for decelerating growth and weaker customer expansion.

Revolution Medicines, Inc. is a clinical-stage precision oncology company, which engages in developing novel targeted therapies. It engages in the discovery and development of cancer treatment by pioneering novel combination and monotherapy treatment regimens to maximize the depth and durability of clinical benefit and circumvent adaptive resistance mechanisms for patients which are dependent on the RAS and mTOR pathway. The company was founded by Mark A. Goldsmith, Kevan Shokat, Martin D. Burke, David L. Pompliano and Michael Fischbach in October 2014 and is headquartered in Redwood City, CA.

Revolution Medicines Inc

Investors are focused on Revolution Medicines upcoming quarterly update for the first full quarter of RASONQUE sales, especially whether new-patient starts show an accelerating launch ramp. Traders are weighing the drugs clinical success and broader pipeline against questions about commercial uptake, competition, and the stocks recent volatility.

Okta, Inc. engages in the provision of an identity management platform for enterprises. The firm operates through the following geographical segments: United States and International. Its products include single sign-on, multi-factor authentication, access gateway, API access management, authentication, adaptive MFA and lifecycle management. The company was founded by Todd McKinnon and J. Frederic Kerrest in 2009 and is headquartered in San Francisco, CA.

Okta Inc - Ordinary Shares - Class A

Okta Inc

Okta is pulling back alongside weakness in cybersecurity and technology stocks, while traders also cite put-heavy options activity and circulate unverified claims of a DHS-related data exposure. The planned S&P 500 inclusion is a bullish counterpoint, but discussion questions whether index-related demand can offset sector pressure and valuation concerns.

Teradyne, Inc. engages in the development and sale of automatic test systems. It operates through the following business segments: Semiconductor Test, Robotics, and All Other. The Semiconductor Test segment designs, manufactures, and markets semiconductor test products and services. The Robotics segment includes operations related to the design, manufacturing, and marketing of collaborative robotic arms, autonomous mobile robots, and advanced robotic control software. The company was founded by Alexander V. d'Arbeloff and Nicholas DeWolf in 1960 and is headquartered in North Reading, MA.

Teradyne, Inc.

Teradynes strong quarterly results are being overshadowed by a selloff as traders question its next-quarter outlook and cite margin pressure, product mix, and competition. Bulls point to AI-driven chip-testing demand, while bearish comments and put-heavy options positioning reflect concern that the growth outlook may not justify the stocks valuation.

Chainlink (LINK) is a cryptocurrency launched in 2017and operates on the Ethereum platform. Chainlink has a current supply of 1,000,000,000 with 748,099,970.42488396 in circulation. The last known price of Chainlink is 11.67852871 USD and is up 2.18 over the last 24 hours. It is currently trading on 2313 active market(s) with $325,834,414.23 traded over the last 24 hours. More information can be found at https://chain.link/.

ChainLink

LINKs sharp rally and elevated trading activity have sparked bullish calls for a breakout, while traders debate whether it can clear resistance or will pull back. Supporters point to Chainlinks institutional and tokenization integrations, while skeptics question whether network adoption will translate into value for the LINK token.

Precigen, Inc. is a biotechnology company, which engages in the research and development of synthetic biology technologies. It operates through the Biopharmaceuticals and Exemplar segments. The company was founded by Thomas David Reed in 1998 and is headquartered in Germantown, MD.

Precigen Inc

Inovios FDA accelerated approval of Voceryq, a competing treatment for recurrent respiratory papillomatosis, has raised concerns about competition for Precigens PAPZIMEOS and prompted a sharp selloff. Traders disagree over the threat, weighing Voceryqs potential to reduce surgeries against PAPZIMEOSs commercial head start and full-approval status, while questioning Inovios reimbursement and launch execution.

TRON (TRX) is a cryptocurrency launched in 2018. TRON has a current supply of 95,022,365,191.094644 with 95,022,375,662.737444 in circulation. The last known price of TRON is 0.30232528 USD and is down -8.04 over the last 24 hours. It is currently trading on 1389 active market(s) with $1,465,217,312.79 traded over the last 24 hours. More information can be found at https://trondao.org/.

Tron

TRON is drawing attention for its relatively steady price action and repeated technical-trading discussion, with many posts describing consolidation or a pullback after a rally. Traders are split between viewing the dip as a healthy pause with long-term strength and worrying that TRX is lagging or could fall further.

Twist Bioscience Corp. engages in the development of a proprietary semiconductor-based synthetic DNA manufacturing process. It operates through the following geographical segments: Americas, EMEA, and APAC. The Americas segment consists of the United States of America, Canada, Mexico, and South America. The EMEA segment includes Europe, Middle East, and Africa. The APAC segment focuses on Japan, China, South Korea, India, Singapore, Malaysia, and Australia. The company was founded by William Marine Banyai, Emily Marine Leproust, and Bill James Peck in 2013 and is headquartered in San Francisco, CA.

Twist Bioscience Corp

TWST is drawing attention after a sharp, high-volume selloff following a steep rally, with traders linking the move to profit-taking and a broader pullback across speculative genomics and biotech stocks rather than a clearly identified company-specific catalyst. The community is split between bearish concerns about valuation and insider selling and bullish claims of short pressure or market manipulation.

Onyxcoin (XCN) is a cryptocurrency launched in 2021and operates on the Ethereum platform. Onyxcoin has a current supply of 53,402,422,627.32441369 with 40,400,796,729.46127832 in circulation. The last known price of Onyxcoin is 0.00378971 USD and is down -1.54 over the last 24 hours. It is currently trading on 205 active market(s) with $5,616,621.35 traded over the last 24 hours. More information can be found at https://onyx.org.

Onyxcoin

Onyxs ecosystem expansionparticularly discussion of a Robinhood Chain testnet bridge involving ETH and tokenized TSLAis drawing attention, with some traders seeing potential in tokenized assets and payments. Others focus on XCNs weakness and volatile spikes, questioning whether the developments are translating into sustained demand.

OFFICIAL TRUMP (TRUMP) is a cryptocurrency and operates on the Solana platform. OFFICIAL TRUMP has a current supply of 999,998,811.032761 with 281,866,747.320393 in circulation. The last known price of OFFICIAL TRUMP is 1.57555883 USD and is down -1.93 over the last 24 hours. It is currently trading on 744 active market(s) with $126,884,732.61 traded over the last 24 hours. More information can be found at https://gettrumpmemes.com/.

Trump For President

TRUMP memecoins steep decline from its launch highs and reported losses among retail holders dominate discussion, with many traders calling it a pump-and-dump while others argue for accumulating or expect a rebound. The debate is closely tied to backlash over Trump and his familys crypto ventures, though claims of a deliberate scam remain traders opinions.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

3 Promising Genomics Stocks to Add to Your Portfolio Now 

Genomics and synthetic biology are transforming healthcare through precision medicine and gene editing, putting ILMN, QURE and TXG in focus as the markets expand.

Butterfly Network, Inc. (BFLY) Reports Q3 Loss, Beats Revenue Estimates

Butterfly Network (BFLY) delivered earnings and revenue surprises of +66.67% and +16.05%, respectively, for the quarter ended September 2026. Do the numbers hold clues to what lies ahead for the stock?

10x Genomics to Participate in the 2026 Jefferies Global Healthcare Conference

10x Genomics to Participate in the 2026 Jefferies Global Healthcare Conference 10x Genomics to Participate in the 2026 Jefferies Global Healthcare ConferencePR NewswirePLEASANTON, Calif., Oct. 27, 2026 PLEASANTON, Calif., Oct. 27, 2026 /PRNewswire/ -- 10x Genomics, Inc.(Nasdaq: TXG), the life...

Wednesday's ETF Movers: WSML, KWEB

In trading on Wednesday, the iShares MSCI World Small-Cap ETF is outperforming other ETFs, up about 3.7% on the day. Components of that ETF showing particular strength include shares of Absci, up about 8.4% and shares of 10x Genomics, up about 8.4% on the day.

And underperform...

Cathie Wood-Led Ark Invest's Biggest Q3 Winners And Losers — PLTR, NVDA, TXG Led While TSLA, RKLB Dragged

Equity

Ark's latest quarterly report shows that several stocks made meaningful contributions across multiple ETFs.

10x Genomics to Report Third Quarter 2026 Financial Results on November 5, 2026

10x Genomics to Report Third Quarter 2026 Financial Results on November 5, 2026 10x Genomics to Report Third Quarter 2026 Financial Results on November 5, 2026PR NewswirePLEASANTON, Calif., Oct. 13, 2026PLEASANTON, Calif., Oct. 13, 2026 /PRNewswire/ -- 10x Genomics, Inc.(Nasdaq: TXG), the life...

10x Genomics & Fred Hutch Join Forces on Cancer Biomarker Research

TXG teams up with Fred Hutchinson Cancer Center to advance precision oncology through single-cell and spatial technologies targeting two cancer types.

10x Genomics Announces New Collaboration to Advance Single Cell and Spatial Applications Across Solid Tumors and Blood Cancers

10x Genomics Announces New Collaboration to Advance Single Cell and Spatial Applications Across Solid Tumors and Blood Cancers 10x Genomics Announces New Collaboration to Advance Single Cell and Spatial Applications Across Solid Tumors and Blood CancersPR NewswirePLEASANTON, Calif., Oct. 7...

Cathie Wood Loads Up On These Biotech Stocks After Strong Rallies – Unloads $18M Worth Of TWST Shares

Across the ARK Genomic Revolution ETF and the ARK Innovation ETF, Wood bought $6.1 million in Recursion Pharmaceuticals, $1.2 million in Intellia Therapeutics, and $5.3 million in Veracyte.


Cathie Wood’s ARKG Is Crushing Her Other ETFs: 2 Biotech Bets Have Surged Nearly 6X This Year 

Twist’s Lilly agreement and involvement in Anthropic research highlight its role in building and testing AI-designed proteins.

10X Genomics, Inc. is a life science technology company, which engages in building products to interrogate, understand and master biology. Its integrated solutions include single cell transcriptomics, single cell genomics, single cell epigenomes, linked-reads genomics and spatial transcriptomics. The company’s products include Single Cell Gene Expression, Immune Profiling, ATAC, and Genome. The company was founded by Serge Saxonov, Ben Hindson and Kevin D. Ness on July 2, 2012 and is headquartered in Pleasanton, CA.

10x Genomics Inc - Ordinary Shares - Class A

Bearish Sentiment

<ul class="summary-bullets"><li>10x Genomics and Palantir were among the standout winners across Ark's portfolios.</li><li>Ark attributed the 10x Genomics rally to growing interest in single-cell sequencing and spatial analysis as sources of data for AI drug-discovery models.</li><li>Nvidia also made the cut, particularly across Ark's technology-focused portfolios.</li></ul>Cathie Wood-led Ark Invest's portfolios saw some dramatic winners and losers in the third quarter (Q3), with artificial intelligence, biotech, crypto and other disruptive-technology bets among the biggest drivers.Ark's latest quarterly report shows that several stocks made meaningful contributions across multiple ETFs, while Tesla Inc. (TSLA) and Rocket Lab Corp. (RKLB) emerged among the most notable drags. Ark's attribution figures measure each holding's contribution to its ETF's performance, rather than the stock's standalone return.<h2 class="st-heading-2">Ark’s Biggest Winners In Q3</h2>10x Genomics Inc. (TXG) was the standout winner across Ark's portfolios. The stock contributed 9.03 percentage points to ARK Genomic Revolution ETF’s (ARKG) 28.92% Q3 gain and 2.92 points to ARK Innovation ETF’s (ARKK) 10.39% return during the quarter.Ark attributed the rally to growing interest in single-cell sequencing and spatial analysis as sources of data for AI drug-discovery models. The firm also highlighted the launch of 10x's Atera spatial system, with orders already in place for the 40 shipments anticipated in 2026.Twist Bioscience Corp. (TWST) was another major biotech winner, contributing 6.51 points to ARKG and 2.55 points to ARKK. The stock jumped 87.83% during the quarter. Ark said Twist was increasingly recognized as a beneficiary of AI-driven drug discovery, including through its protein-characterization work for Anthropic.&nbsp;Tempus AI Inc. (TEM) also stood out, contributing 3.21 points to ARKG and 2.08 points to ARKK, while gaining 41.38% during the quarter.&nbsp;Then there was Palantir Technologies Inc. (PLTR), emerging as one of the most important cross-ETF winners. Palantir contributed 1.86 points to ARK Autonomous Technology &amp; Robotics ETF (ARKQ), 1.62 points to ARKK, 1.48 points to ARK Next Generation Technology ETF (ARKW), 2.39 points to ARK Blockchain &amp; Fintech Innovation ETF (ARKF) and 1.47 points to ARK Space &amp; Defense Innovation ETF (ARKX).Nvidia Corp. (NVDA) also made the cut, particularly across Ark's technology-focused portfolios. It contributed 0.49 points to ARKQ and 0.48 points to ARKX.<h2 class="st-heading-2">Biggest Losers</h2>Tesla was the clearest recurring drag across Ark's portfolios. It was the biggest detractor in ARKQ (-1.72 percentage points), ARKK (-1.75 points) and ARKW (-1.43 points).Ark said Tesla sold off sharply after its second-quarter (Q2) results disappointed on profitability, with price cuts and the wind-down of the Model S and Model X pressuring margins.But the firm also pointed to a recovery in the stock as Tesla publicly launched Cybercab in Austin and surpassed 1 million unsupervised robotaxi miles, up from 380,000 just six weeks earlier.Rocket Lab was another major drag, particularly in the space-focused portfolios. It contributed -1.39 points to ARKQ and -2.04 points to ARKX.The firm noted that Rocket Lab completed 21 flights in 2025 and had a backlog of more than 90 missions as of the second quarter.Ark's biggest winners included AI, AI-enabled biotech and other technology bets, while some of its highest-profile holdings, most notably Tesla and Rocket Lab, weighed on performance.<a href="https://stocktwits.com/symbol/ARKK">ARKK ETF</a> declined nearly 5% in Friday’s regular trading session and fell nearly 0.4% during the after-hours trade. Retail sentiment on Stocktwits around ARKK trended in the ‘bearish’ territory at the time of writing.Also See:&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/trump-denies-spacex-starlink-slowed-down-white-house-elon-musk/cZxkR3ARBtB">Trump Denies SpaceX’s Starlink Was Slowed Down Over Ukraine By Either White House Or Elon Musk: Report</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

Cathie Wood, chief executive officer and chief investment officer, Ark Invest, gestures as she speaks during the Bitcoin 2022 Conference at Miami Beach Convention Center on April 7, 2022. (Photo by Marco Bello/Getty Images)

Cathie Wood-Led Ark Invest's Biggest Q3 Winners and Losers — PLTR, NVDA, TXG Led While TSLA, RKLB Dragged

ARK Fintech Innovation ETF

ARK Investment Management LLC - ARK Genomic Revolution ETF

ARK Innovation ETF

ARK Next Generation Internet ETF

ARK Space Exploration & Innovation ETF

Palantir Technologies Inc

Rocket Lab USA Inc

Tempus AI Inc

Hold rates steady

Cut 25 bps

Hike 25 bps

Fed decision day is here - Kevin Warsh chairs his first FOMC meeting with markets pricing a hold at 3.50%-3.75% but watching for a hawkish shift. Vote on what you expect to be decided today, then drop your prediction for the first rate cut or hike in the comments.

What do you expect the Fed to decide at its FOMC meeting today? 
 
Drop a comment with when you expect the first cut/hike to be.

Current Price	$70.11
Prev Close	$81.55
Open	$73.65
Dividend Yield	0.00%
50-Day Moving Average	$74.17
Beta	2.01
Avg. Volume	2.95M
PE Ratio	-118.89

52-Week High	$102.81
52-Week Low	$12.80
Market Capitalization	$9.13B
EPS (Annual)	-$0.3491
Price to Book	11.06
Revenue Per Employee	$545,690.15

Feed

News

Sentiment

Earnings

Fundamentals

Info

TXG Fundamentals